blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2844271

EP2844271 - USE OF FOLLISTATIN OR OF AN ACTIVIN INHIBITOR FOR PREVENTING OR TREATING TISSUE GRAFT DYSFUNCTION [Right-click to bookmark this link]
Former [2015/11]A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME
[2017/37]
StatusNo opposition filed within time limit
Status updated on  04.01.2019
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  26.01.2018
FormerGrant of patent is intended
Status updated on  19.01.2018
FormerExamination is in progress
Status updated on  03.01.2018
FormerGrant of patent is intended
Status updated on  31.08.2017
FormerExamination is in progress
Status updated on  03.02.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Paranta Biosciences Limited
189-191 Balaclava Road
Caulfield VIC 3161 / AU
[2015/11]
Inventor(s)01 / DE KRETSER, David
1 Leura Street
Surrey Hills, Victoria 3127 / AU
02 / O'HEHIR, Robyn
120 Gatehouse Street
Parkville, Victoria 3052 / AU
 [2015/51]
Former [2015/11]01 / DE KRETSER, David
1 Leura Street
Surrey Hills, Victoria 3127 / AU
02 / O'HEHIR, Robyn
120 Gatehouse Street
Parkville, Victoria 3052 / AU
03 / CHEN, Yi
41 Seaview Avenue
Bentleigh, Victoria 3204 / AU
Representative(s)Weickmann & Weickmann PartmbB
Postfach 860 820
81635 München / DE
[2018/09]
Former [2015/11]Weickmann, Hans, et al
Weickmann & Weickmann
Postfach 860 820
81635 München / DE
Application number, filing date13791008.917.05.2013
[2018/09]
WO2013AU00520
Priority number, dateAU2012090203617.05.2012         Original published format: AU 2012902036
AU2012090540211.12.2012         Original published format: AU 2012905402
[2015/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013170315
Date:21.11.2013
Language:EN
[2013/47]
Type: A1 Application with search report 
No.:EP2844271
Date:11.03.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 21.11.2013 takes the place of the publication of the European patent application.
[2015/11]
Type: B1 Patent specification 
No.:EP2844271
Date:28.02.2018
Language:EN
[2018/09]
Search report(s)International search report - published on:AU21.11.2013
(Supplementary) European search report - dispatched on:EP09.10.2015
ClassificationIPC:A61K38/17, A61K38/22, A61K38/58, C07K14/575, A61K35/12, A61P37/06
[2017/37]
CPC:
A61K38/22 (EP,US); A61K38/1709 (EP,US); A61K38/1796 (EP,US);
A61K38/55 (EP,US); A61K38/58 (EP,US); A61P37/06 (EP);
C07K14/575 (EP,US); C07K16/22 (EP,US); C07K2317/30 (EP,US) (-)
C-Set:
A61K35/12, A61K2300/00 (EP,US)
Former IPC [2015/45]A61K38/17, A61P37/06, A61K35/12, C07K14/47, A61K41/00
Former IPC [2015/11]A61K38/17, A61P37/06
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/11]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERWENDUNG VON FOLLISTATIN ODER ACTIVIN INHIBITOREN ZUR PROPHYLAXIS ODER THERAPIE EINER GEWEBETRANSPLANTATSDYSFUNKTION[2017/37]
English:USE OF FOLLISTATIN OR OF AN ACTIVIN INHIBITOR FOR PREVENTING OR TREATING TISSUE GRAFT DYSFUNCTION[2017/37]
French:UTILISATION DE LA FOLLISTATINE OU D'UN INHIBITEUR DE L'ACTIVINE POUR PRÉVENIR OU TRAITER LE DYSFONCTIONNEMENT D'UNE GREFFE TISSULAIRE[2017/37]
Former [2015/11]BEHANDLUNGSVERFAHREN UND MITTEL DAFÜR
Former [2015/11]A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME
Former [2015/11]PROCÉDÉ DE TRAITEMENT ET AGENTS UTILES POUR CELUI-CI
Entry into regional phase10.09.2014National basic fee paid 
10.09.2014Search fee paid 
10.09.2014Designation fee(s) paid 
10.09.2014Examination fee paid 
Examination procedure10.09.2014Examination requested  [2015/11]
21.06.2016Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
28.07.2016Amendment by applicant (claims and/or description)
07.02.2017Despatch of a communication from the examining division (Time limit: M04)
06.06.2017Reply to a communication from the examining division
01.09.2017Communication of intention to grant the patent
02.01.2018Fee for grant paid
02.01.2018Fee for publishing/printing paid
03.01.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
18.01.2018Information about intention to grant a patent
18.01.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  07.02.2017
Opposition(s)29.11.2018No opposition filed within time limit [2019/06]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
28.07.2016Request for further processing filed
28.07.2016Full payment received (date of receipt of payment)
Request granted
09.08.2016Decision despatched
Fees paidRenewal fee
12.05.2015Renewal fee patent year 03
10.05.2016Renewal fee patent year 04
24.04.2017Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.05.2013
AL28.02.2018
AT28.02.2018
CY28.02.2018
CZ28.02.2018
DK28.02.2018
EE28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
MC28.02.2018
MK28.02.2018
NL28.02.2018
PL28.02.2018
PT28.02.2018
RO28.02.2018
RS28.02.2018
SE28.02.2018
SI28.02.2018
SK28.02.2018
SM28.02.2018
TR28.02.2018
IE17.05.2018
LU17.05.2018
MT17.05.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
IS28.06.2018
[2020/33]
Former [2020/31]HU17.05.2013
AL28.02.2018
AT28.02.2018
CY28.02.2018
CZ28.02.2018
DK28.02.2018
EE28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
MC28.02.2018
MK28.02.2018
NL28.02.2018
PL28.02.2018
PT28.02.2018
RO28.02.2018
RS28.02.2018
SE28.02.2018
SI28.02.2018
SK28.02.2018
SM28.02.2018
TR28.02.2018
IE17.05.2018
LU17.05.2018
MT17.05.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
Former [2020/28]HU17.05.2013
AL28.02.2018
AT28.02.2018
CY28.02.2018
CZ28.02.2018
DK28.02.2018
EE28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
MC28.02.2018
NL28.02.2018
PL28.02.2018
PT28.02.2018
RO28.02.2018
RS28.02.2018
SE28.02.2018
SI28.02.2018
SK28.02.2018
SM28.02.2018
TR28.02.2018
IE17.05.2018
LU17.05.2018
MT17.05.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
Former [2020/16]AL28.02.2018
AT28.02.2018
CY28.02.2018
CZ28.02.2018
DK28.02.2018
EE28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
MC28.02.2018
NL28.02.2018
PL28.02.2018
RO28.02.2018
RS28.02.2018
SE28.02.2018
SI28.02.2018
SK28.02.2018
SM28.02.2018
TR28.02.2018
IE17.05.2018
LU17.05.2018
MT17.05.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
Former [2020/08]AL28.02.2018
AT28.02.2018
CY28.02.2018
CZ28.02.2018
DK28.02.2018
EE28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
MC28.02.2018
NL28.02.2018
PL28.02.2018
RO28.02.2018
RS28.02.2018
SE28.02.2018
SI28.02.2018
SK28.02.2018
SM28.02.2018
IE17.05.2018
LU17.05.2018
MT17.05.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
Former [2019/24]AL28.02.2018
AT28.02.2018
CY28.02.2018
CZ28.02.2018
DK28.02.2018
EE28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
MC28.02.2018
NL28.02.2018
PL28.02.2018
RO28.02.2018
RS28.02.2018
SE28.02.2018
SI28.02.2018
SK28.02.2018
SM28.02.2018
IE17.05.2018
LU17.05.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
Former [2019/19]AL28.02.2018
AT28.02.2018
CY28.02.2018
CZ28.02.2018
DK28.02.2018
EE28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
MC28.02.2018
NL28.02.2018
PL28.02.2018
RO28.02.2018
RS28.02.2018
SE28.02.2018
SI28.02.2018
SK28.02.2018
SM28.02.2018
IE17.05.2018
LU17.05.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
CH31.05.2018
LI31.05.2018
Former [2019/17]AL28.02.2018
AT28.02.2018
CY28.02.2018
CZ28.02.2018
DK28.02.2018
EE28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
MC28.02.2018
NL28.02.2018
PL28.02.2018
RO28.02.2018
RS28.02.2018
SE28.02.2018
SI28.02.2018
SK28.02.2018
SM28.02.2018
LU17.05.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
CH31.05.2018
LI31.05.2018
Former [2019/12]AL28.02.2018
AT28.02.2018
CY28.02.2018
CZ28.02.2018
DK28.02.2018
EE28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
MC28.02.2018
NL28.02.2018
PL28.02.2018
RO28.02.2018
RS28.02.2018
SE28.02.2018
SI28.02.2018
SK28.02.2018
SM28.02.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
CH31.05.2018
LI31.05.2018
Former [2019/06]AL28.02.2018
AT28.02.2018
CY28.02.2018
CZ28.02.2018
DK28.02.2018
EE28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
MC28.02.2018
NL28.02.2018
PL28.02.2018
RO28.02.2018
RS28.02.2018
SE28.02.2018
SK28.02.2018
SM28.02.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
Former [2018/52]AL28.02.2018
AT28.02.2018
CY28.02.2018
CZ28.02.2018
DK28.02.2018
EE28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
NL28.02.2018
PL28.02.2018
RO28.02.2018
RS28.02.2018
SE28.02.2018
SK28.02.2018
SM28.02.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
Former [2018/51]AL28.02.2018
AT28.02.2018
CY28.02.2018
CZ28.02.2018
DK28.02.2018
EE28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
NL28.02.2018
PL28.02.2018
RO28.02.2018
RS28.02.2018
SE28.02.2018
SK28.02.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
Former [2018/50]AL28.02.2018
AT28.02.2018
CY28.02.2018
CZ28.02.2018
EE28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
NL28.02.2018
PL28.02.2018
RO28.02.2018
RS28.02.2018
SE28.02.2018
SK28.02.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
Former [2018/46]AL28.02.2018
AT28.02.2018
CY28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
NL28.02.2018
RS28.02.2018
SE28.02.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
Former [2018/40]AT28.02.2018
CY28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
LV28.02.2018
NL28.02.2018
RS28.02.2018
SE28.02.2018
BG28.05.2018
NO28.05.2018
GR29.05.2018
Former [2018/37]CY28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
NL28.02.2018
NO28.05.2018
GR29.05.2018
Former [2018/35]CY28.02.2018
FI28.02.2018
HR28.02.2018
LT28.02.2018
NL28.02.2018
NO28.05.2018
Documents cited:Search[Y]US2002028762  (KOJIMA ITARU [JP]) [Y] 1-15* see claims and ex.3 *;
 [XP]  - FAKHFAKH RAOUIA ET AL, "Administration of a Soluble Activin Type IIB Receptor Promotes the Transplantation of Human Myoblasts in Dystrophic Mice", CELL TRANSPLANTATION, (20120630), vol. 21, no. 7, pages 1419 - 1430, XP002745054 [XP] 1,2,5,6,14 * see abstract, pages 1426-1427 *

DOI:   http://dx.doi.org/10.3727/096368911X627480
 [Y]  - KANAMOTO MAMI ET AL, "Beneficial Effects of Follistatin in Hepatic Ischemia-Reperfusion Injuries in Rats", DIGESTIVE DISEASES AND SCIENCES, (201104), vol. 56, no. 4, pages 1075 - 1081, XP002745055 [Y] 1-15 * see abstract, p.1075 right col., p.1080 left col. *

DOI:   http://dx.doi.org/10.1007/s10620-010-1401-4
International search[X]WO02080952  (LORANTIS LTD [GB], et al);
 [X]WO2004022730  (LORANTIS LTD [GB], et al);
 [X]WO2005032578  (UNIV MONASH [AU], et al);
 [X]US2008181869  (DEVORE DIANNA LOUISE [US]);
 [X]  - EL-AGGAN, H. A. ET AL., "STUDY OF SERUM ACTIVIN A AND FOLLISTATIN IN POST RENAL TRANSPLANT PATIENTS: CORRELATION WITH RENAL HEMODYNAMICS, GRAFT FUNCTION AND SURVIVAL", BUL. ALEX. FAC. MED., (2008), vol. 44, no. 4, pages 699 - 707, XP055161702
by applicantUS5753187
 US5763263
    - BUNIN ET AL., PROC NATL ACAD SCI USA, (1994), vol. 91, pages 4708 - 4712
    - DEWITT ET AL., PROC NATL A CAD SCI USA, (1993), vol. 90, pages 6909 - 6913
    - ELBASHIR ET AL., METHODS, (2000), vol. 26, pages 199 - 213
    - DING, NUCL ACIDS RES, vol. 32, pages W135 - W141
    - DING; LAWRENCE, NUCL ACIDS RES, (2003), vol. 31, pages 7280 - 7301
    - DING; LAWRENCE, NUCL ACIDS RES, (2001), vol. 20, pages 1034 - 1046
    - EGLETON; DAVIS, PEPTIDES, (1997), pages 1431 - 1439
    - LANGER, SCIENCE, (1990), vol. 249, pages 1527 - 1533
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.